Market Research

View All

pharma-news
Eli Lilly’s COVID-19 Antibody trial; Approval for Oriahnn; Gilead’s Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19

Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555.  LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people g...

Find More

DelveInsight Logo
Introducing a new brand identity, and a new website: DelveInsight.

Today we’re unveiling a new identity and launching a new logo.  For any company, to get a new logo designed might look like a cakewalk; however, it is exactly the opposite. This is a big deal because we are highly recognized by our old one in our industry, among our clients, employees, business partners, an...

Find More

cancer
Gold Nanoparticles May Soon Treat Prostate Cancer

Gold nanoparticles may soon turn out to be a Prostate cancer treatment option. Apparently, there are certain risks associated with conventional cancer treatments such as uncontrolled bleeding, fatal blood clots and dangerous reactions to the anaesthetic, among others. To relieve patients from such risks, a new clini...

Find More

parkinson's
Parkinson’s and tuberculosis shares a common protein that could provide better drugs for both

A group of researchers has recently discovered that an immune mechanism responsible in clearing bacterial infections may also be involved in causing Parkinson's disease. The study has identified the role of protein LRRK2 in tuberculosis, results have shown that it behaves similarly in Parkinson disease. This finding...

Find More

Hematopoietic stem cells
Hematopoietic Stem Cell Transplantation

Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages. Stromal interactions with soluble and cell-bound cytokines structures the differentiations and proliferation of hematopoietic cells. Hematopoietic stem cell transplantation (HSCT) is the i...

Find More

Delveinsight
Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commerc...

Find More

Delveinsight
Hepatic Encephalopathy- Lack of active pipeline products

Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-standing or chronic liver disorder are at high risk. The disease may also be triggered by bleeding in the digestive tract,...

Find More

SANOFI
Cholesterol drug Praluent successful in reducing heart risk

Sanofi and Regeneron Pharmaceuticals got effective results in reducing the risk of major adverse heart events in a clinical study of nearly 19,000 patients with the help of cholesterol drug Praluent. Drugmakers now hope that the results are good enough to convince insurers to pay for the pricey medicine. Treatment w...

Find More

Delveinsight
Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market

Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. The number of Diagnosed Prevalent Population of Transthyre...

Find More

transthyretin amyloidosis
CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff

Rice University researchers tested CRISPR to cure sickle cell, now preparing for upcoming challenges A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of the total stem cell samples taken from affected patients. Although the results are quite pro...

Find More